Diagnostic Considerations for Discordant Fecal Biomarkers

Diagnostic Performance of Fecal Biomarkers

Fecal lactoferrin has a sensitivity of 83% (95% CI, 72%-90%) and specificity of 75% (95% CI, 59%-87%) for detecting moderate to severe endoscopic inflammation in inflammatory bowel disease (IBD) 1
Fecal calprotectin at a cutoff of 150 ± 50 mg/g has a sensitivity of 71% (95% CI, 62%-78%) and specificity of 69% (95% CI, 62%-75%) for detecting moderate to severe endoscopic inflammation 1

Discordance between normal calprotectin and elevated lactoferrin may reflect segmental disease that might be missed by calprotectin alone 2

For patients with normal calprotectin but elevated lactoferrin and mild symptoms, endoscopic assessment is recommended rather than empiric treatment adjustment 2
For asymptomatic patients with this discordant pattern, repeat biomarker measurement in 3-6 months is suggested before proceeding to endoscopy 2
If endoscopy confirms inflammation despite normal calprotectin, treatment should be adjusted based on endoscopic findings, and both biomarkers should continue to be monitored to establish which correlates better with the patient's disease activity 2

Medications, particularly NSAIDs used in the past 6 weeks, can affect biomarker levels and should be considered when interpreting discordant results 2
Different collection and processing methods can affect stability and measurement of these biomarkers 3

Rule out infections first, particularly C. difficile and other enteric pathogens, as these can cause elevated inflammatory markers 4
For patients with moderate to severe symptoms and elevated lactoferrin (even with normal calprotectin), consider treatment adjustment without routine endoscopic assessment 4
For patients with mild symptoms and discordant markers, proceed with endoscopic assessment to confirm the presence or absence of inflammation 4, 2
If endoscopy shows no inflammation despite elevated lactoferrin, consider other causes such as infections or medications, and repeat lactoferrin testing in 3-6 months 2

The American Gastroenterological Association (AGA) recommends using fecal calprotectin >150 μg/g or elevated fecal lactoferrin to rule in active inflammation and inform treatment adjustment while avoiding endoscopic assessment solely for establishing disease presence 5
With both markers elevated and moderate-to-severe symptoms, the false positive rate is only 4.6%, meaning 95.4% of patients truly have moderate to severe endoscopic inflammation, and treatment can be adjusted empirically without requiring endoscopy first 5
The AGA specifically recommends endoscopic assessment rather than empiric treatment adjustment in patients with mild symptoms and elevated biomarkers, as the false positive rate for moderate-to-severe inflammation is 15.5% in this scenario 5

Repeat fecal calprotectin measurement 2-4 months after initiating or adjusting therapy to monitor response, as both calprotectin and lactoferrin decline significantly with successful anti-TNF therapy 5